Immune%20Potentiating%20Agents_2010

Immune%20Potentiating%20Agents_2010 - Objectives Immune...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
1 Immune Potentiating Agents Trinh Pham, PharmD, BCOP Associate Clinical Professor PHRX 4041 Immunology Module Objectives Students should be able to: s Granulocyte Colony Stimulating Factors (G-CSF) s Identify the indications for the use of G-CSF s Indicate when to administer and discontinue these agents s Recommend options to treat side effects s Interferon s Recognize the difference between acute and chronic side effects s Recommend how to manage side effects s Interleukine -2 (IL-2) s Recognize the side effects associated with IL-2 s Recommend appropriate agents to prevent or treat the side effects 2 hours 33 hours 3.5 hours Half-Life Stimulates granulocytes, macrophages, and eosinophils Yeast derived product Covalent conjugate of filgrastim and monomethoxy- polyethylene glycol Same MOA as G-CSF Stimulates the activation, proliferation and differentiation of neutrophil progenitor cells Enhances the function of mature neutrophils E.Coli. derived product MOA Sargramostim (Leukine ® ) (GM-CSF) Pegfilgrastim (Neulasta ® ) Filgrastim (Neupogen ® ) (G-CSF) Sargramostim Pegfilgrastim Filgrastim Bone Marrow Transplant or Acute Myelogenous Leukemia 24 hours after completion of chemotherapy Myelotoxic Chemotherapy 24 hours after completion of chemotherapy Myelotoxic Chemotherapy 24 to 72 hours after myelotoxic chemotherapy High Dose Chemotherapy with Autologous Stem Cell Rescue 24 to 120 hours after administration of high dose chemotherapy Peripheral Blood Progenitor Cell (PBPC) Mobilization Start at least 4 days before 1 st leukapheresis Non- Oncology Indications for filgrastim s Agranulocytosis s AIDS – Neutropenia s 5-10 mcg/kg/day for 2-4 weeks s Myelodysplastic Syndrome (GM-CSF also indicated) s Neutropenic Disorders – chronic severe, symptomatic s Congenital - 6 mcg/kg SC twice daily s Idiopathic or cyclic – 5 mcg/kg/day SC Sargramostim Pegfilgrastim Filgrastim Continue until ANC is > 1.5 to 3 x 10 3 /ml for three consecutive days Once in each chemotherapy cycle Myelotoxic Chemotherapy or High Dose Chemotherapy with Autologous Stem Cell Rescue: Continue until ANC is at least 2 to 3 x 10 3 /ml or total WBC is > 5 x 10 3 /ml Peripheral Blood Progenitor Cell (PBPC) Mobilization Continue until last leukapheresis Dura- tion of Therapy
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
2 1 x 10 3 /mm 3 3 10 --- --- 72 --- --- 1.4 March 14 65 --- --- % Granulocytes 1.99 x 10 3 /mm 3 --- --- --- --- 34 49 2.4 March 13 38-71 --- --- % Segs 0-10 --- --- % Bands 1.9 x 10 3 /mm 3 --- 4 12 --- 2.9 March 12 0-5 --- % Eosinophils Normal March 15 650 neutro- phil cells ANC (x 10 3 / mm 3 ) 2-15 --- % Monocytes 14-46 --- % Lymphocytes 38-81 --- % Neutrophils 4-10 1 WBC (x 10 3 / mm 3 ) Sargramostim Pegfilgrastim Filgrastim 250 mcg/m 2 /day for all clinical settings 6 mg Do not administer 14 days before and 24
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 10/08/2011 for the course PHAR 4030 taught by Professor Dr.miller during the Spring '11 term at UConn.

Page1 / 6

Immune%20Potentiating%20Agents_2010 - Objectives Immune...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online